Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

The interaction between RUNX2 and core binding factor beta as a potential therapeutic target in canine osteosarcoma.

Alegre F, Ormonde AR, Godinez DR, Illendula A, Bushweller JH, Wittenburg LA.

Vet Comp Oncol. 2019 Aug 5. doi: 10.1111/vco.12526. [Epub ahead of print]

PMID:
31381810
2.

RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1.

Mill CP, Fiskus W, DiNardo CD, Qian Y, Raina K, Rajapakshe K, Perera D, Coarfa C, Kadia TM, Khoury JD, Saenz DT, Saenz DN, Illendula A, Takahashi K, Kornblau SM, Green MR, Futreal AP, Bushweller JH, Crews CM, Bhalla KN.

Blood. 2019 Jul 4;134(1):59-73. doi: 10.1182/blood.2018893982. Epub 2019 Apr 25.

PMID:
31023702
3.

RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation.

Zhou N, Gutierrez-Uzquiza A, Zheng XY, Chang R, Vogl DT, Garfall AL, Bernabei L, Saraf A, Florens L, Washburn MP, Illendula A, Bushweller JH, Busino L.

Leukemia. 2019 Aug;33(8):2006-2021. doi: 10.1038/s41375-019-0403-2. Epub 2019 Feb 13.

4.

CBFβ-SMMHC Inhibition Triggers Apoptosis by Disrupting MYC Chromatin Dynamics in Acute Myeloid Leukemia.

Pulikkan JA, Hegde M, Ahmad HM, Belaghzal H, Illendula A, Yu J, O'Hagan K, Ou J, Muller-Tidow C, Wolfe SA, Zhu LJ, Dekker J, Bushweller JH, Castilla LH.

Cell. 2018 Aug 23;174(5):1325. doi: 10.1016/j.cell.2018.08.014. No abstract available.

PMID:
30142347
5.

CBFβ-SMMHC Inhibition Triggers Apoptosis by Disrupting MYC Chromatin Dynamics in Acute Myeloid Leukemia.

Pulikkan JA, Hegde M, Ahmad HM, Belaghzal H, Illendula A, Yu J, O'Hagan K, Ou J, Muller-Tidow C, Wolfe SA, Zhu LJ, Dekker J, Bushweller JH, Castilla LH.

Cell. 2018 Jun 28;174(1):172-186.e21. doi: 10.1016/j.cell.2018.05.048. Erratum in: Cell. 2018 Aug 23;174(5):1325.

6.

Small molecule inhibition of the CBFβ/RUNX interaction decreases ovarian cancer growth and migration through alterations in genes related to epithelial-to-mesenchymal transition.

Carlton AL, Illendula A, Gao Y, Llaneza DC, Boulton A, Shah A, Rajewski RA, Landen CN, Wotton D, Bushweller JH.

Gynecol Oncol. 2018 May;149(2):350-360. doi: 10.1016/j.ygyno.2018.03.005. Epub 2018 Mar 16.

7.

Solution structure and elevator mechanism of the membrane electron transporter CcdA.

Zhou Y, Bushweller JH.

Nat Struct Mol Biol. 2018 Feb;25(2):163-169. doi: 10.1038/s41594-018-0022-z. Epub 2018 Jan 29.

8.

A tool compound targeting the core binding factor Runt domain to disrupt binding to CBFβ in leukemic cells.

Oo ZM, Illendula A, Grembecka J, Schmidt C, Zhou Y, Esain V, Kwan W, Frost I, North TE, Rajewski RA, Speck NA, Bushweller JH.

Leuk Lymphoma. 2018 Sep;59(9):2188-2200. doi: 10.1080/10428194.2017.1410882. Epub 2017 Dec 18.

9.

Corrigendum to: "Small Molecule Inhibitor of CBFβ-RUNX Binding for RUNX Transcription Factor Driven Cancers" [EBioMedicine 8 (2016) 117-131].

Illendula A, Gilmour J, Grembecka J, Tirumala VSS, Boulton A, Kuntimaddi A, Schmidt C, Wang L, Pulikkan JA, Zong H, Parlak M, Kuscu C, Pickin A, Zhou Y, Gao Y, Mishra L, Adli M, Castilla LH, Rajewski RA, Janes KA, Guzman ML, Bonifer C, Bushweller JH.

EBioMedicine. 2017 Nov;25:188. doi: 10.1016/j.ebiom.2017.10.029. Epub 2017 Oct 31. No abstract available.

10.

RUNX1 is required for oncogenic Myb and Myc enhancer activity in T-cell acute lymphoblastic leukemia.

Choi A, Illendula A, Pulikkan JA, Roderick JE, Tesell J, Yu J, Hermance N, Zhu LJ, Castilla LH, Bushweller JH, Kelliher MA.

Blood. 2017 Oct 12;130(15):1722-1733. doi: 10.1182/blood-2017-03-775536. Epub 2017 Aug 8.

11.

Bacillus anthracis Peptidoglycan Integrity Is Disrupted by the Chemokine CXCL10 through the FtsE/X Complex.

Margulieux KR, Liebov BK, Tirumala VSKKS, Singh A, Bushweller JH, Nakamoto RK, Hughes MA.

Front Microbiol. 2017 Apr 27;8:740. doi: 10.3389/fmicb.2017.00740. eCollection 2017.

12.

Molecular Basis and Targeted Inhibition of CBFβ-SMMHC Acute Myeloid Leukemia.

Castilla LH, Bushweller JH.

Adv Exp Med Biol. 2017;962:229-244. doi: 10.1007/978-981-10-3233-2_15. Review.

PMID:
28299661
13.

Small Molecule Inhibitor of CBFβ-RUNX Binding for RUNX Transcription Factor Driven Cancers.

Illendula A, Gilmour J, Grembecka J, Tirumala VSS, Boulton A, Kuntimaddi A, Schmidt C, Wang L, Pulikkan JA, Zong H, Parlak M, Kuscu C, Pickin A, Zhou Y, Gao Y, Mishra L, Adli M, Castilla LH, Rajewski RA, Janes KA, Guzman ML, Bonifer C, Bushweller JH.

EBioMedicine. 2016 Jun;8:117-131. doi: 10.1016/j.ebiom.2016.04.032. Epub 2016 Apr 29. Erratum in: EBioMedicine. 2017 Nov;25:188.

14.

MAPK/ERK2 phosphorylates ERG at serine 283 in leukemic cells and promotes stem cell signatures and cell proliferation.

Huang Y, Thoms JA, Tursky ML, Knezevic K, Beck D, Chandrakanthan V, Suryani S, Olivier J, Boulton A, Glaros EN, Thomas SR, Lock RB, MacKenzie KL, Bushweller JH, Wong JW, Pimanda JE.

Leukemia. 2016 Jul;30(7):1552-61. doi: 10.1038/leu.2016.55. Epub 2016 Mar 8.

15.

Tom1 Modulates Binding of Tollip to Phosphatidylinositol 3-Phosphate via a Coupled Folding and Binding Mechanism.

Xiao S, Brannon MK, Zhao X, Fread KI, Ellena JF, Bushweller JH, Finkielstein CV, Armstrong GS, Capelluto DGS.

Structure. 2015 Oct 6;23(10):1910-1920. doi: 10.1016/j.str.2015.07.017. Epub 2015 Aug 27.

16.

Degree of recruitment of DOT1L to MLL-AF9 defines level of H3K79 Di- and tri-methylation on target genes and transformation potential.

Kuntimaddi A, Achille NJ, Thorpe J, Lokken AA, Singh R, Hemenway CS, Adli M, Zeleznik-Le NJ, Bushweller JH.

Cell Rep. 2015 May 5;11(5):808-20. doi: 10.1016/j.celrep.2015.04.004. Epub 2015 Apr 23.

17.

Chemical biology. A small-molecule inhibitor of the aberrant transcription factor CBFβ-SMMHC delays leukemia in mice.

Illendula A, Pulikkan JA, Zong H, Grembecka J, Xue L, Sen S, Zhou Y, Boulton A, Kuntimaddi A, Gao Y, Rajewski RA, Guzman ML, Castilla LH, Bushweller JH.

Science. 2015 Feb 13;347(6223):779-84. doi: 10.1126/science.aaa0314.

18.

Importance of a specific amino acid pairing for murine MLL leukemias driven by MLLT1/3 or AFF1/4.

Lokken AA, Achille NJ, Chang MJ, Lin JJ, Kuntimaddi A, Leach BI, Malik B, Nesbit JB, Zhang S, Bushweller JH, Zeleznik-Le NJ, Hemenway CS.

Leuk Res. 2014 Nov;38(11):1309-15. doi: 10.1016/j.leukres.2014.08.010. Epub 2014 Aug 24.

19.

Functional specificity of CpG DNA-binding CXXC domains in mixed lineage leukemia.

Risner LE, Kuntimaddi A, Lokken AA, Achille NJ, Birch NW, Schoenfelt K, Bushweller JH, Zeleznik-Le NJ.

J Biol Chem. 2013 Oct 11;288(41):29901-10. doi: 10.1074/jbc.M113.474858. Epub 2013 Aug 29.

20.

Structural and dynamic studies of the transcription factor ERG reveal DNA binding is allosterically autoinhibited.

Regan MC, Horanyi PS, Pryor EE Jr, Sarver JL, Cafiso DS, Bushweller JH.

Proc Natl Acad Sci U S A. 2013 Aug 13;110(33):13374-9. doi: 10.1073/pnas.1301726110. Epub 2013 Jul 29.

21.

Leukemia fusion target AF9 is an intrinsically disordered transcriptional regulator that recruits multiple partners via coupled folding and binding.

Leach BI, Kuntimaddi A, Schmidt CR, Cierpicki T, Johnson SA, Bushweller JH.

Structure. 2013 Jan 8;21(1):176-183. doi: 10.1016/j.str.2012.11.011. Epub 2012 Dec 20.

22.

Optimal mutation sites for PRE data collection and membrane protein structure prediction.

Chen H, Ji F, Olman V, Mobley CK, Liu Y, Zhou Y, Bushweller JH, Prestegard JH, Xu Y.

Structure. 2011 Apr 13;19(4):484-95. doi: 10.1016/j.str.2011.02.002.

23.

Application of fragment-based drug discovery to membrane proteins: identification of ligands of the integral membrane enzyme DsbB.

Früh V, Zhou Y, Chen D, Loch C, Ab E, Grinkova YN, Verheij H, Sligar SG, Bushweller JH, Siegal G.

Chem Biol. 2010 Aug 27;17(8):881-91. doi: 10.1016/j.chembiol.2010.06.011.

24.

Structure of the AML1-ETO NHR3-PKA(RIIα) complex and its contribution to AML1-ETO activity.

Corpora T, Roudaia L, Oo ZM, Chen W, Manuylova E, Cai X, Chen MJ, Cierpicki T, Speck NA, Bushweller JH.

J Mol Biol. 2010 Sep 24;402(3):560-77. doi: 10.1016/j.jmb.2010.08.007. Epub 2010 Aug 11.

25.

The PHD3 domain of MLL acts as a CYP33-regulated switch between MLL-mediated activation and repression .

Park S, Osmers U, Raman G, Schwantes RH, Diaz MO, Bushweller JH.

Biochemistry. 2010 Aug 10;49(31):6576-86. doi: 10.1021/bi1009387.

26.

Structure of the MLL CXXC domain-DNA complex and its functional role in MLL-AF9 leukemia.

Cierpicki T, Risner LE, Grembecka J, Lukasik SM, Popovic R, Omonkowska M, Shultis DD, Zeleznik-Le NJ, Bushweller JH.

Nat Struct Mol Biol. 2010 Jan;17(1):62-8. doi: 10.1038/nsmb.1714. Epub 2009 Dec 13.

27.

The role of CBFbeta in AML1-ETO's activity.

Park S, Speck NA, Bushweller JH.

Blood. 2009 Sep 24;114(13):2849-50. doi: 10.1182/blood-2009-07-231233. No abstract available.

28.

The solution structure and dynamics of the DH-PH module of PDZRhoGEF in isolation and in complex with nucleotide-free RhoA.

Cierpicki T, Bielnicki J, Zheng M, Gruszczyk J, Kasterka M, Petoukhov M, Zhang A, Fernandez EJ, Svergun DI, Derewenda U, Bushweller JH, Derewenda ZS.

Protein Sci. 2009 Oct;18(10):2067-79. doi: 10.1002/pro.219.

29.

On the mechanism of autoinhibition of the RhoA-specific nucleotide exchange factor PDZRhoGEF.

Zheng M, Cierpicki T, Momotani K, Artamonov MV, Derewenda U, Bushweller JH, Somlyo AV, Derewenda ZS.

BMC Struct Biol. 2009 May 21;9:36. doi: 10.1186/1472-6807-9-36.

30.

Structure of the AML1-ETO eTAFH domain-HEB peptide complex and its contribution to AML1-ETO activity.

Park S, Chen W, Cierpicki T, Tonelli M, Cai X, Speck NA, Bushweller JH.

Blood. 2009 Apr 9;113(15):3558-67. doi: 10.1182/blood-2008-06-161307. Epub 2009 Feb 9.

31.

CBFbeta is critical for AML1-ETO and TEL-AML1 activity.

Roudaia L, Cheney MD, Manuylova E, Chen W, Morrow M, Park S, Lee CT, Kaur P, Williams O, Bushweller JH, Speck NA.

Blood. 2009 Mar 26;113(13):3070-9. doi: 10.1182/blood-2008-03-147207. Epub 2009 Jan 29.

32.

NMR solution structure of the integral membrane enzyme DsbB: functional insights into DsbB-catalyzed disulfide bond formation.

Zhou Y, Cierpicki T, Jimenez RH, Lukasik SM, Ellena JF, Cafiso DS, Kadokura H, Beckwith J, Bushweller JH.

Mol Cell. 2008 Sep 26;31(6):896-908. doi: 10.1016/j.molcel.2008.08.028.

33.

MLL protects CpG clusters from methylation within the Hoxa9 gene, maintaining transcript expression.

Erfurth FE, Popovic R, Grembecka J, Cierpicki T, Theisler C, Xia ZB, Stuart T, Diaz MO, Bushweller JH, Zeleznik-Le NJ.

Proc Natl Acad Sci U S A. 2008 May 27;105(21):7517-22. doi: 10.1073/pnas.0800090105. Epub 2008 May 15.

34.

Allosteric inhibition of the protein-protein interaction between the leukemia-associated proteins Runx1 and CBFbeta.

Gorczynski MJ, Grembecka J, Zhou Y, Kong Y, Roudaia L, Douvas MG, Newman M, Bielnicka I, Baber G, Corpora T, Shi J, Sridharan M, Lilien R, Donald BR, Speck NA, Brown ML, Bushweller JH.

Chem Biol. 2007 Oct;14(10):1186-97.

35.

Structural basis for recognition of SMRT/N-CoR by the MYND domain and its contribution to AML1/ETO's activity.

Liu Y, Chen W, Gaudet J, Cheney MD, Roudaia L, Cierpicki T, Klet RC, Hartman K, Laue TM, Speck NA, Bushweller JH.

Cancer Cell. 2007 Jun;11(6):483-97.

36.

Disease mutations in RUNX1 and RUNX2 create nonfunctional, dominant-negative, or hypomorphic alleles.

Matheny CJ, Speck ME, Cushing PR, Zhou Y, Corpora T, Regan M, Newman M, Roudaia L, Speck CL, Gu TL, Griffey SM, Bushweller JH, Speck NA.

EMBO J. 2007 Feb 21;26(4):1163-75. Epub 2007 Feb 8.

37.

A mutation in the S-switch region of the Runt domain alters the dynamics of an allosteric network responsible for CBFbeta regulation.

Li Z, Lukasik SM, Liu Y, Grembecka J, Bielnicka I, Bushweller JH, Speck NA.

J Mol Biol. 2006 Dec 15;364(5):1073-83. Epub 2006 Oct 4.

38.

The DC-module of doublecortin: dynamics, domain boundaries, and functional implications.

Cierpicki T, Kim MH, Cooper DR, Derewenda U, Bushweller JH, Derewenda ZS.

Proteins. 2006 Sep 1;64(4):874-82.

PMID:
16835924
40.

The tetramer structure of the Nervy homology two domain, NHR2, is critical for AML1/ETO's activity.

Liu Y, Cheney MD, Gaudet JJ, Chruszcz M, Lukasik SM, Sugiyama D, Lary J, Cole J, Dauter Z, Minor W, Speck NA, Bushweller JH.

Cancer Cell. 2006 Apr;9(4):249-60.

42.

The binding of the PDZ tandem of syntenin to target proteins.

Grembecka J, Cierpicki T, Devedjiev Y, Derewenda U, Kang BS, Bushweller JH, Derewenda ZS.

Biochemistry. 2006 Mar 21;45(11):3674-83.

PMID:
16533050
43.

High resolution structure of the HDGF PWWP domain: a potential DNA binding domain.

Lukasik SM, Cierpicki T, Borloz M, Grembecka J, Everett A, Bushweller JH.

Protein Sci. 2006 Feb;15(2):314-23. Epub 2005 Dec 29.

45.

Allosteric activation of protein phosphatase 2C by D-chiro-inositol-galactosamine, a putative mediator mimetic of insulin action.

Brautigan DL, Brown M, Grindrod S, Chinigo G, Kruszewski A, Lukasik SM, Bushweller JH, Horal M, Keller S, Tamura S, Heimark DB, Price J, Larner AN, Larner J.

Biochemistry. 2005 Aug 23;44(33):11067-73. Erratum in: Biochemistry. 2005 Nov 22;44(46):15422.

PMID:
16101290
46.

Probing the supramodular architecture of a multidomain protein: the structure of syntenin in solution.

Cierpicki T, Bushweller JH, Derewenda ZS.

Structure. 2005 Feb;13(2):319-27.

47.
48.

CBFbeta allosterically regulates the Runx1 Runt domain via a dynamic conformational equilibrium.

Yan J, Liu Y, Lukasik SM, Speck NA, Bushweller JH.

Nat Struct Mol Biol. 2004 Sep;11(9):901-6. Epub 2004 Aug 22.

PMID:
15322525
49.

Synthesis and evaluation of substituted 4-aryloxy- and 4-arylsulfanyl-phenyl-2-aminothiazoles as inhibitors of human breast cancer cell proliferation.

Gorczynski MJ, Leal RM, Mooberry SL, Bushweller JH, Brown ML.

Bioorg Med Chem. 2004 Mar 1;12(5):1029-36.

PMID:
14980616
50.

Supplemental Content

Loading ...
Support Center